Karyopharm Therapeutics Inc
Clinical trials sponsored by Karyopharm Therapeutics Inc, explained in plain language.
-
Last-Resort cancer drug made available to patients before approval
Disease control AVAILABLEThis program offers early access to the investigational drug selinexor for people with certain advanced cancers, such as multiple myeloma, lymphoma, sarcoma, and others, who have no other treatment options. Patients must not qualify for any ongoing clinical trial and must have ex…
Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug hope for myelofibrosis patients with low platelets
Disease control Recruiting nowThis Phase 2 trial tests the drug selinexor in people with myelofibrosis who have not taken JAK inhibitors and have low to normal platelet counts. The main goal is to see if selinexor can shrink the spleen by at least 35% after 24 weeks. Researchers will also check if it improves…
Phase: PHASE2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for patients with advanced multiple myeloma: drug combo shows promise
Disease control Recruiting nowThis study tests a drug called selinexor combined with a low-dose steroid (dexamethasone) in people with multiple myeloma that has stopped responding to many other treatments. Some participants will also receive another drug, bortezomib. The goal is to see if these combinations c…
Phase: PHASE2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC